Lenograstim
When ATH:
L03AA10
Pharmacological action.
Leukopoietic.
Application.
Neutropenia: after chemotherapy (primary and secondary prevention), Idiopathic, Congenital, cyclic, patients AIDS; neutropenic infection, intensification of chemotherapy, obtaining hematopoietic stem cells for future protection of hematopoiesis, prevention of infection after surgery, severe infection in non-cancer patients (in combination with antibiotics).
Contraindications.
Hypersensitivity, myeloproliferative disease, severe liver and kidney, pregnancy, breast-feeding.
Side effects.
Myalgia, ossalgia, fever, leukocytosis, thrombocytopenia, soreness at the injection site.
Dosing and Administration.
P /, I /, dose 19,2 million IU / m2, 1 once a day. The contents of the ampoule were dissolved in water for injection immediately before use; million IU / m 100 ml saline. million IU / m (to 28 days), to achieve and maintain the number of cells at the level of 10,000 / microliter within 3 days. To mobilize hematopoietic progenitor cells during chemotherapy, daily administration begins 24–48 hours after the last chemotherapeutic agent is discontinued.. In the treatment of severe infections in patients with a normal white blood cell count in adults - at a dose 33,6 In the treatment of severe infections in patients with a normal white blood cell count in adults - at a dose. For the prevention of infectious complications in plastic surgery on the esophagus: for 2 of the day before surgery and for a further 7 days thereafter.
Precautions.
The total duration of treatment with daily administration should not exceed 4 Sun. Showed regular monitoring of white blood cells and platelets in the peripheral blood. In the presence of marked leukocytosis (> 50In the treatment of severe infections in patients with a normal white blood cell count in adults - at a dose9 /l) We need a break. When bone pain or fever is recommended that a NSAID. Against the background of antitumor chemotherapy, the introduction of lenograstim is started 24-48 hours after the end of chemotherapy and is canceled on the last day before the start of the next course..
Cooperation
Active substance | Description of interaction |
Mitomycin | FMR. Against the background of lenograstima may increase bone marrow toxicity (especially the platelet germ). |